Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound?-Reference-Cited by-同舟云学术

Two-Year Clinical Outcomes of the CONSEQUENT Trial: Can Femoropopliteal Lesions be Treated with Sustainable Clinical Results that are Economically Sound?

Published:2018-03-27 Issue:7 Volume:41 Page:1008-1014
ISSN:0174-1551
Container-title:CardioVascular and Interventional Radiology
language:en
Short-container-title:Cardiovasc Intervent Radiol

Author:

Albrecht Thomas,Waliszewski Matthias,Roca Catherine,Redlich Ulf,Tautenhahn Jörg,Pech Maciej,Halloul Zuhir,Gögebakan Özlem,Meyer Dirk-Roelfs,Gemeinhardt Ines,Zeller Thomas,Müller-Hülsbeck Stefan,Ott Ilka,Tepe Gunnar

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology Nuclear Medicine and imaging

Link

https://link.springer.com/article/10.1007/s00270-018-1940-1/fulltext.html

Reference20 articles.

1. Tepe G, Gögebakan Ö, Redlich U, et al. Angiographic and clinical outcomes after treatment of femoro-popliteal lesions with a novel paclitaxel-matrix-coated balloon catheter. Cardiovasc Intervent Radiol. 2017;40(10):1535–44.

2. Herten M, Torsello GB, Schönefeld E, Stahlhoff S. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease. Vasc Health Risk Manag. 2016;12:341–56.

3. Laird JR, Schneider PA, Tepe G, et al. IN.PACT SFA trial investigators. Durability of Treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–38.

4. Salisbury AC, Li H, Vilain KR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9(22):2343–52.

5. Pietzsch JB, Geisler BP, Garner AM, Zeller T, Jaff MR. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84(4):546–54.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Robustness of Longitudinal Safety and Efficacy After Paclitaxel-Based Endovascular Therapy for Treatment of Femoro-Popliteal Artery Occlusive Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials;Annals of Vascular Surgery;2024-04

2. Mortality, Safety, and Effectiveness of Paclitaxel-Containing Balloons and Stents in the Femoropopliteal Artery: Systematic Review and Meta-Analysis of Randomized Controlled Trials since 2018;Journal of Vascular and Interventional Radiology;2024-02

3. Novel Endovascular Technologies in Femoropopliteal Disease;Mastering Endovascular Techniques;2024

4. The Pharmacological Properties of Red Grape Polyphenol Resveratrol: Clinical Trials and Obstacles in Drug Development;Nutrients;2023-10-23

5. Clinical investigation of the GORE drug-coated PTA balloon catheter for CE mark approval;Expert Review of Medical Devices;2023-05-16